JP2021517152A5 - - Google Patents
Info
- Publication number
- JP2021517152A5 JP2021517152A5 JP2020549021A JP2020549021A JP2021517152A5 JP 2021517152 A5 JP2021517152 A5 JP 2021517152A5 JP 2020549021 A JP2020549021 A JP 2020549021A JP 2020549021 A JP2020549021 A JP 2020549021A JP 2021517152 A5 JP2021517152 A5 JP 2021517152A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- acid sequence
- seq
- amino acid
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862643334P | 2018-03-15 | 2018-03-15 | |
| US201862643355P | 2018-03-15 | 2018-03-15 | |
| US62/643,334 | 2018-03-15 | ||
| US62/643,355 | 2018-03-15 | ||
| US201862774254P | 2018-12-02 | 2018-12-02 | |
| US62/774,254 | 2018-12-02 | ||
| PCT/IL2019/050292 WO2019175885A1 (en) | 2018-03-15 | 2019-03-14 | Methods and compositions for decreasing soluble immune receptor cd28 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517152A JP2021517152A (ja) | 2021-07-15 |
| JP2021517152A5 true JP2021517152A5 (enExample) | 2022-03-23 |
| JP7691823B2 JP7691823B2 (ja) | 2025-06-12 |
Family
ID=66182618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020549021A Active JP7691823B2 (ja) | 2018-03-15 | 2019-03-14 | 可溶性免疫受容体ｃｄ２８を減少させるための方法および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12139534B2 (enExample) |
| EP (1) | EP3765518A1 (enExample) |
| JP (1) | JP7691823B2 (enExample) |
| KR (1) | KR20200131260A (enExample) |
| CN (2) | CN119775419A (enExample) |
| AU (1) | AU2019234183B2 (enExample) |
| BR (1) | BR112020018279A2 (enExample) |
| CA (1) | CA3093647A1 (enExample) |
| IL (1) | IL277354B2 (enExample) |
| WO (1) | WO2019175885A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019234183B2 (en) | 2018-03-15 | 2025-12-18 | Biond Biologics Ltd. | Methods and compositions for decreasing soluble immune receptor CD28 |
| EP3938397A1 (en) | 2019-03-14 | 2022-01-19 | Biond Biologics Ltd. | Small shedding blocking agents |
| CA3130348A1 (en) * | 2019-03-14 | 2020-09-17 | Motti HAKIM | A method for immunosuppression |
| WO2021111442A1 (en) | 2019-12-02 | 2021-06-10 | Biond Biologics Ltd. | Soluble cd28 levels during immunotherapy |
| JP2023509803A (ja) * | 2019-12-02 | 2023-03-09 | ビオンド バイオロジクス リミテッド | Ｍｍｐ抑制の使用 |
| US20230221325A1 (en) * | 2019-12-02 | 2023-07-13 | Biond Biologics Ltd. | Soluble cd28 levels after immunotherapy |
| CN115515982A (zh) * | 2020-03-12 | 2022-12-23 | 比昂生物制剂公司 | 具有增加的稳定性的脱落阻断剂 |
| EP4399229A2 (en) | 2021-09-06 | 2024-07-17 | Biond Biologics Ltd. | Cd28 shedding blocking agents |
| EP4499706A2 (en) * | 2022-03-31 | 2025-02-05 | Sana Biotechnology, Inc. | Cd4-specific antibody constructs and compositions and uses thereof |
| WO2025149029A1 (zh) * | 2024-01-12 | 2025-07-17 | 信达生物制药(苏州)有限公司 | 抗cd28抗体及其用途 |
| WO2025215647A1 (en) | 2024-04-11 | 2025-10-16 | Biond Biologics Ltd. | Combination cancer treatment with staggered dosing |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| DK1345969T3 (da) | 2000-12-26 | 2010-11-29 | Inst Nat Sante Rech Med | Anti-CD28-antistof |
| CN1294148C (zh) * | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| IL148993A0 (en) | 2002-04-04 | 2002-11-10 | Yissum Res Dev Co | Broad-spectrum in-vivo effective superantigen toxin antagonists based on the interaction between cd28 and the superantigen and uses thereof |
| EP1622569B1 (en) | 2003-04-24 | 2015-12-02 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metallproteases |
| GB0400440D0 (en) | 2004-01-09 | 2004-02-11 | Isis Innovation | Receptor modulators |
| CN100509849C (zh) | 2005-04-07 | 2009-07-08 | 苏州大学 | 可溶性人cd28分子检测试剂盒及其应用 |
| PE20110385A1 (es) | 2008-07-18 | 2011-06-22 | Bristol Myers Squibb Co | Anticuerpo de dominio (dab) que se une a cd28 y no reacciona en forma cruzada con ctla4 |
| AU2019234183B2 (en) | 2018-03-15 | 2025-12-18 | Biond Biologics Ltd. | Methods and compositions for decreasing soluble immune receptor CD28 |
-
2019
- 2019-03-14 AU AU2019234183A patent/AU2019234183B2/en active Active
- 2019-03-14 IL IL277354A patent/IL277354B2/en unknown
- 2019-03-14 BR BR112020018279-6A patent/BR112020018279A2/pt not_active IP Right Cessation
- 2019-03-14 CA CA3093647A patent/CA3093647A1/en active Pending
- 2019-03-14 KR KR1020207027789A patent/KR20200131260A/ko active Pending
- 2019-03-14 EP EP19717979.9A patent/EP3765518A1/en active Pending
- 2019-03-14 JP JP2020549021A patent/JP7691823B2/ja active Active
- 2019-03-14 US US16/980,409 patent/US12139534B2/en active Active
- 2019-03-14 WO PCT/IL2019/050292 patent/WO2019175885A1/en not_active Ceased
- 2019-03-14 CN CN202411963509.6A patent/CN119775419A/zh active Pending
- 2019-03-14 CN CN201980029648.2A patent/CN112074539B/zh active Active
-
2024
- 2024-06-06 US US18/735,940 patent/US20240309094A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517152A5 (enExample) | ||
| JP7150880B2 (ja) | 抗－ｂ７－ｈ３抗体およびその用途 | |
| AU2019218516B2 (en) | Antibodies to T cell immunoreceptor with Ig and ITIM domains (TIGIT) and uses thereof | |
| CN112574307B (zh) | 抗人Claudin18.2抗体及其应用 | |
| KR102536145B1 (ko) | 항-pd-1 항체 및 이의 용도 | |
| AU2016233495B2 (en) | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof | |
| JP2021506244A5 (enExample) | ||
| JP2019527553A5 (enExample) | ||
| CN112566662A (zh) | 针对cd47的阻断抗体及其使用方法 | |
| KR20160127825A (ko) | 항-mcam 항체 및 관련된 사용 방법 | |
| CN114380909A (zh) | 特异性针对糖基化的pd-l1的抗体及其使用方法 | |
| NZ585551A (en) | Anti-mesothelin antibodies and uses therefor | |
| US11220543B2 (en) | Antibody binding specifically to CD66c and use thereof | |
| JP2019506391A (ja) | リンパ球における阻害経路の中和 | |
| EP4527465A2 (en) | Anti-glypican 3 antibodies | |
| EP4403574A1 (en) | Protein specifically binding to pd-1 and pharmaceutical use thereof | |
| CN109721656B (zh) | 靶向rankl的治疗性抗体 | |
| US11161905B2 (en) | Recombinant antibodies to programmed death 1 (PD-1) and uses thereof | |
| JP2024001073A5 (enExample) | ||
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| CN116925229B (zh) | 一种靶向gprc5d的抗体及其应用 | |
| US20230221325A1 (en) | Soluble cd28 levels after immunotherapy | |
| KR20190130506A (ko) | 골수유래억제세포 관련 질환의 예방 및 치료 용도 | |
| CN112805297B (zh) | 抗人类pd-l1抗体及其用途 | |
| CN113527484A (zh) | 抗cd47单克隆抗体 |